Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZOLADEX in Premenopausal Women With HR+ Breast Cancer
NCT07310420Phase 1Recruiting
- Sponsor
- TerSera Therapeutics
- Start
- Oct 2026
- Primary completion
- Mar 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of goserelin in hormone receptor-positive breast cancer, sponsored by TerSera Therapeutics. Primary endpoint: Percentage of Participants with Luteinizing Hormone (LH) Values Below a Specified Threshold at 6 weeks. Started Oct 2026; status: recruiting.
02
Drugs
goserelin
03
Conditions
hormone receptor-positive breast cancer
Beyond the preview
Go deeper on NCT07310420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310420.